Nur Nicholson - Sep 18, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Technical Officer
Signature
/s/ David Watson, attorney-in-fact for Nur Nicholson
Stock symbol
APLS
Transactions as of
Sep 18, 2023
Transactions value $
-$611,576
Form type
4
Date filed
9/19/2023, 05:03 PM
Previous filing
Feb 22, 2023
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $289K +9.72K +15.21% $29.76 73.6K Sep 18, 2023 Direct
transaction APLS Common Stock Sale -$410K -9.72K -13.2% $42.21 63.9K Sep 18, 2023 Direct F1
transaction APLS Common Stock Sale -$491K -10.6K -16.63% $46.15 53.3K Sep 18, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -9.72K -7.78% $0.00 115K Sep 18, 2023 Common Stock 9.72K $29.76 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $46.200 - $46.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $46.140 - $46.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This includes 412 shares from 04/30/2023 ESPP purchase.
F4 This stock option was granted on August 17, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.